GHRP-6

GHRP-6 stands for Growth Hormone Releasing Peptide-6. It is a synthetic hexapeptide built from six amino acids in the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂. Two of these building blocks are in the D configuration (D-tryptophan at position 2 and D-phenylalanine at position 5), and the C-terminal end is amidated. Neither feature is a chemical accident: they increase stability against the body's own peptidases and lock in the spatial structure required for receptor binding. The molecular weight is around 873.0 g/mol and the molecular formula is C₄₆H₅₆N₁₂O₆.

GHRP-6 belongs to the class of growth hormone secretagogues (GHS). The term describes molecules that prompt the body to release its own growth hormone (GH) instead of supplying growth hormone from outside. This difference is central to understanding the whole class: GHRP-6 is not growth hormone and does not replace it. It acts one step earlier in the regulatory circuits, at the level of the hypothalamus and pituitary.

Historically, GHRP-6 is one of the earliest members of this class. As early as the late 1980s the hexapeptide was studied in healthy volunteers, where it produced selective stimulation of GH release (Ilson et al., 1989). At that time the corresponding receptor was still unknown. Only in 1996 did a group at Merck clone the G protein coupled receptor in pituitary and hypothalamus at which these secretagogues act (Howard et al., 1996). Three years later, ghrelin was identified as the body's own ligand of this receptor. Seen historically, GHRP-6 was therefore the tool that led to the discovery of an entire hormone system.

For classification today, the regulatory status is decisive: GHRP-6 has no approval as a medicine, neither from the US FDA nor from the European EMA. In catalogues it is typically listed as a substance for research purposes. Everything you read in this guide therefore describes the state of published research and is not a recommendation for use. If you want to look at the general safety assessment of such substances, you will find background in the article on the safety of peptides.

GHRP-6 binds as an agonist to the growth hormone secretagogue receptor type 1a (GHS-R1a), which today is usually simply called the ghrelin receptor. This receptor was cloned in 1996 from pituitary as well as from the arcuate nucleus and the infundibular nucleus of the hypothalamus in pig and human, and was identified as the target of the synthetic secretagogues (Howard et al., 1996). Activation runs through a G protein coupled signalling pathway which, in the somatotroph cells of the pituitary, leads to a rise in intracellular calcium and ultimately to the release of stored growth hormone.

Crucially, GHRP-6 does not act on the pituitary alone. Research in the 1990s showed that the hypothalamus is indispensable for the full effect. In a study of patients with hypothalamic-pituitary disconnection, the GH response to GHRP-6 was completely blocked, and the otherwise typical synergistic effect of GHRP-6 together with GHRH was also absent. The authors concluded that the main site of action of GHRP-6 lies at the hypothalamic level (Popovic et al., 1995).

A second human study refined this picture pharmacologically. When the action of endogenous GHRH was blocked in healthy volunteers, the GH response to GHRP-6 was clearly smaller. For maximal GH stimulation, GHRP-6 therefore needs the body's own GHRH (Pandya et al., 1998). In practical terms this means GHRP-6 amplifies and prolongs an existing physiological release pulse rather than replacing it entirely.

The resulting GH release therefore stays pulsatile, that is, wave-like, and follows the natural rhythm of the pituitary. This fundamentally distinguishes secretagogues from exogenous growth hormone, which can produce persistently elevated levels. Whether this preserved pulsatility really comes with a more favourable safety profile is an assumption that is often made but has never been tested for GHRP-6 in long-term studies.

Pharmacokinetically, GHRP-6 is short-lived. In a study of nine healthy male volunteers after a single intravenous dose, the plasma curve followed a biexponential function with a distribution half-life of 7.6 ± 1.9 minutes and an elimination half-life of 2.5 ± 1.1 hours (Cabrales et al., 2013). Single bolus doses of 100, 200 and 400 µg/kg body weight were studied. These figures describe the study conditions only and are expressly not a dosage recommendation.

The strongest appetite effect within the GHRP family is considered the characteristic feature of GHRP-6. The reason lies in the receptor itself: GHS-R1a is the receptor of ghrelin, the stomach hormone colloquially called the hunger hormone. Activating this receptor touches not only the GH axis but also, at the same time, the central control of hunger and energy balance.

The relevant evidence comes predominantly from animal models. In a widely cited study in rats, intracerebroventricular administration of ghrelin or GHRP-6 produced a significant increase in food intake and a temporary drop in core body temperature. Labelling of c-Fos, an indicator of neuronal activation, made it possible to show which brain regions are involved: arcuate nucleus, paraventricular nucleus, dorsomedial and ventromedial hypothalamus, lateral hypothalamus and areas of the brainstem. In the lateral hypothalamus, orexin-containing neurons were specifically activated, but not neurons containing melanin-concentrating hormone (Lawrence et al., 2002).

For humans the evidence base is thinner than marketing texts suggest. Controlled studies that quantitatively measure food intake after GHRP-6 are rare. The clearest human evidence for this mechanism exists for the related GHRP-2: in a study of seven lean healthy men who received subcutaneous GHRP-2 or saline over 270 minutes, participants consumed about 36 percent more food at a subsequent buffet meal than on placebo (Laferrère et al., 2005). Since both peptides activate the same receptor, a comparable effect for GHRP-6 is considered plausible, but it has not been demonstrated directly in this form.

The flip side matters too: a strong appetite stimulus is not a neutral side effect. It can shift energy balance noticeably and is potentially problematic in contexts involving weight goals, disordered eating or pre-existing metabolic conditions. That very property is also the reason ghrelin receptor agonists were studied at all in research on cachexia and loss of appetite.

The human literature on GHRP-6 consists mainly of small, short-term physiological and diagnostic studies from the 1990s and early 2000s. Typical sample sizes are in the single digits to the low double digits, and observation periods usually range from single hours to a few nights. Endpoints are almost always hormone levels, not clinical outcomes such as body composition, performance or quality of life over months.

An instructive example is the sleep studies from Munich. Repeated intravenous doses of GHRP-6 during night-time sleep raised serum levels of GH, ACTH and cortisol in healthy young men (Frieboes et al., 1995). A follow-up study compared routes of administration and found clear differences: after oral administration in enteric-coated capsules, GH, ACTH and cortisol remained unchanged, while intranasal administration significantly increased night-time GH concentration (Frieboes et al., 1999). This illustrates a general problem with peptides: without a suitable formulation, oral bioavailability is low.

The diagnostic application comes from clinical endocrinology. GHRP-6 was used, partly in combination with GHRH, as a stimulation test to assess pituitary GH reserve, and at the same time helped to localise disorders of the GH axis. Studies in specific populations also exist, for example in type 1 diabetes, where GHRP-6 influenced ACTH and cortisol as well as GH (de Sá et al., 2010).

A second research strand, mainly from Cuba, investigates GHRP-6 beyond the GH axis as a potentially cytoprotective substance. In a preclinical wound healing model, full-thickness skin wounds were created in Wistar rats and hypertrophic scars in rabbits, then treated topically with a preparation containing GHRP-6 at a concentration of 400 µg/mL. The authors described a damping of immune-inflammatory mediators and reduced expression of fibrotic cytokines (Mendoza Marí et al., 2016). This work is in animal models and cannot be transferred to humans.

The honest summary is this: there is plenty of mechanistic research, some informative acute human physiology and practically no controlled long-term studies on efficacy or safety in healthy adults. Reviews of the substance class reach a similarly cautious verdict and point, among other things, to possible worsening of insulin sensitivity under secretagogues (Sigalos and Pastuszak, 2018).

All three substances activate the same receptor but differ in potency and selectivity. GHRP-2 is considered a more potent secretagogue than GHRP-6 with a weaker appetite effect. Ipamorelin was developed specifically for selectivity. In the original paper describing Ipamorelin as the first selective growth hormone secretagogue, GHRP-6 and GHRP-2 raised plasma levels of ACTH and cortisol, while Ipamorelin did not stimulate these hormones more than GHRH did. Notably for the prolactin discussion: in that study none of the tested secretagogues significantly affected levels of FSH, LH, prolactin or TSH (Raun et al., 1998).

The overview below summarises the profile differences described in the literature. It does not replace a case-by-case assessment and contains no information about use.

A detailed head-to-head comparison of GHRP-6 and GHRP-2 would go beyond the scope of this guide and can be found in the separate GHRP-2 monograph. For the more selective alternative, it is worth looking at the Ipamorelin guide, which covers the safety profile of that pentapeptide in detail.

One point of context remains important: more selective does not automatically mean safer. Robust long-term human data are missing for Ipamorelin as well. The differences concern the acute hormone profile, not the question of whether years of use would be harmless.

Combining a secretagogue with a GHRH analogue rests on a physiologically understandable rationale. The two classes act at different receptors: GHRP-6 at the ghrelin receptor GHS-R1a, GHRH analogues at the GHRH receptor of the somatotroph cells. In human studies in the 1990s, giving GHRH and GHRP-6 together produced GH release clearly above the sum of the individual effects.

That the two pathways are connected is shown by the study already mentioned, in which blocking endogenous GHRH weakened the GH response to GHRP-6 (Pandya et al., 1998). GHRP-6 therefore depends on a functioning GHRH tone. Conversely, GHRP-6 presumably suppresses inhibitory somatostatin influences. That explains why the combination acts synergistically in acute test situations.

In practice, in the research literature this logic appears mainly in diagnostic stimulation tests, not as an established treatment regimen. In informal contexts, by contrast, it is often transferred to combinations such as CJC-1295. For background on this combination logic, see the article on the CJC-1295 and Ipamorelin stack, which describes the same two-receptor idea with the more selective partner peptide.

From a scientific point of view, restraint is called for here. An acute synergistic effect on a hormone level is not evidence of clinical benefit over weeks or months. For none of these combinations do controlled long-term studies on efficacy or safety in healthy adults exist. Approved GHRH analogues such as Sermorelin or Tesamorelin earned their indications in clearly defined clinical situations, not in general performance or anti-ageing use.

If you want to follow the pure reconstitution mathematics of such research peptides, you can use the GHRP-6 calculator in our Peptide Lab application. The tool converts volumes and concentrations only, and deliberately gives no recommendation on amounts, frequency or use.

The best documented hormonal side effect is co-activation of the hypothalamic-pituitary-adrenal axis. In human studies, ACTH and cortisol rose alongside GH after GHRP-6 administration (Frieboes et al., 1995; de Sá et al., 2010), and in direct comparison with Ipamorelin, GHRP-6 was among the secretagogues with a measurable ACTH and cortisol effect (Raun et al., 1998). A persistently raised cortisol level would be undesirable from an endocrinological point of view, because it affects metabolism, immune function and sleep. Whether the acute increases observed in the studies persist with repeated use has not been investigated.

For prolactin the factual basis is weaker than often claimed. Increases in prolactin have mainly been described for related secretagogues such as Hexarelin and GHRP-2. In the comparative study by Raun and colleagues, none of the tested secretagogues, GHRP-6 included, changed prolactin levels significantly. Anyone presenting a marked rise in prolactin as an established property of GHRP-6 is going beyond the published data.

Further points discussed in the literature on this substance class are:

• Metabolic effects: reviews of growth hormone secretagogues name possible worsening of insulin sensitivity with a rise in blood glucose as a relevant safety signal (Sigalos and Pastuszak, 2018).
• Appetite and energy balance: the pronounced orexigenic effect can lead to an unintended increase in calorie intake.
• Water retention and joint complaints: classic accompanying effects of raised GH and IGF-1 levels, known from GH therapy and plausible for secretagogues, but not systematically quantified for GHRP-6.
• Local reactions and quality risks: products without pharmaceutical approval are subject to no regulatory quality control, so purity, identity and sterility are not guaranteed.

Two groups deserve particular caution: people with existing disorders of glucose metabolism and people with hormone-active or oncological conditions, since activation of the GH and IGF-1 axis could theoretically be unfavourable here. No robust quantification of risk exists for GHRP-6.

Medical note: this list is for information and does not replace medical advice. Discuss health questions with a qualified medical professional.

GHRP-6 is not approved as a medicine in any major jurisdiction. There is no FDA approval and no EMA approval for any human indication. In practice the substance is sold as a research chemical, often with the note that it is not intended for human use. That note is not a formality: it describes the actual regulatory status.

The legal assessment of manufacture, import, possession and supply differs considerably between countries and changes over time. In the European Union and in Switzerland, unapproved substances with pharmacological activity typically fall under the respective medicines legislation. In Germany and Austria, sports-law and medicines-law rules on handling doping agents apply in addition. Always check the status for your own country before making assumptions.

In the anti-doping context, by contrast, the situation is unambiguous. The Prohibited List of the World Anti-Doping Agency (WADA) includes, in section S2, the category of peptide hormones, growth factors, related substances and mimetics. Within that section, the growth hormone releasing factors cover both growth hormone secretagogues and their mimetics and the GH releasing peptides (GHRPs), and GHRP-6 is named there explicitly, alongside GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5, Hexarelin and alexamorelin, among others. Substances in this section are prohibited at all times, that is, in competition and out of competition.

For athletes this means that use of GHRP-6 constitutes an anti-doping rule violation, regardless of whether it is declared as a supplement, a research peptide or a medical measure. Since the Prohibited List is updated annually, you should check the currently valid version on the official WADA website before any decision, rather than relying on secondary sources.

Despite forty years of research history, central questions about GHRP-6 remain unanswered. The biggest gap concerns long-term safety in humans. No published controlled studies exist that followed healthy adults on GHRP-6 over months or years while recording metabolic, cardiovascular or oncological endpoints. Everything that goes beyond short-term hormone responses is extrapolation.

Second, it is unclear whether repeated stimulation of the ghrelin receptor leads to desensitisation. Rapid receptor desensitisation has been described in vitro for related secretagogues. Whether and to what extent the GH response to GHRP-6 fades with continued use has not been systematically studied in humans.

Third, a robust statement on clinical relevance is missing. A measurable rise in GH over a few hours says little about whether body composition, bone density, recovery or sleep quality change in the long run. Reviews of the substance class describe possible effects on appetite, lean mass and sleep, but at the same time stress the limited data quality and the signal of reduced insulin sensitivity (Sigalos and Pastuszak, 2018).

Fourth, the cytoprotective findings beyond the GH axis are interesting but immature. The work on wound healing and on damping fibrotic cytokines comes from rodent and rabbit models (Mendoza Marí et al., 2016). The step to controlled clinical trials in humans has not been taken to any relevant extent for these indications.

Finally, the question of product quality remains open. Without approval there is no binding testing of identity, purity and sterility. For that reason too, we carry no GHRP-6 product in our catalogue and deliberately link to no source of supply. If you engage with this substance class, do so with a clear view of what the literature shows and of what it leaves open.

Note: this article is for educational purposes only. GHRP-6 is a research peptide with no medicines approval for human use. It does not constitute medical advice and contains no dosage recommendations. Consult a doctor before health-related decisions.